NEW YORK, September 15, 2016 /PRNewswire/ --
Stock-Callers.com is currently assessing four Generic Drugs equities,
On Wednesday, shares in Solana Beach, California headquartered Evoke Pharma Inc. recorded a trading volume of 220,767 shares. The stock ended the day at $1.92, climbing 1.59%. The Company's shares are trading below its 50-day moving average by 43.52%. Furthermore, shares of Evoke Pharma, which primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases, have a Relative Strength Index (RSI) of 41.14.
On September 7th, 2016, Evoke Pharma announced that it has completed a pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate, Gimoti™, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. The focus of this pre-NDA meeting with the FDA was the content of the regulatory, chemistry, manufacturing, and control (CMC), and non-clinical sections of the Company's planned 505(b)(2) NDA for Gimoti. Access our complete research report on EVOK for free at:
Chesterfield, the UK-based Mallinckrodt PLC's stock finished yesterday's session 1.02% higher at $75.33 and with a total trading volume of 1.40 million shares. The Company's shares have gained 25.30% over the previous three months and 0.94% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.24% and 13.90%, respectively. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents in the US, Europe, the Middle East, Africa, and internationally, have an RSI of 52.59.
On August 31st, 2016, Mallinckrodt announced that it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft® regenerative skin tissue and a technology platform for genetically enhanced skin tissues.
On August 31st, 2016, research firm Deutsche Bank reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $87 a share to $84 a share. The complimentary research report on MNK can be downloaded at:
At the closing bell on Wednesday, shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. saw a decline of 2.08%, ending the day at $0.95. The stock recorded a trading volume of 283,149 shares. The Company's shares have advanced 26.07% in the last one month and 20.92% in the previous three months. The stock is trading 11.35% above its 50-day moving average. Moreover, shares of Catalyst Pharmaceuticals, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 50.06.
On September 2nd, 2016, Catalyst Pharmaceuticals announced that the FDA has granted the company orphan drug designation for Firdapse® (amifampridine phosphate) for the treatment of myasthenia gravis. Orphan Drug designation is granted by the FDA's Office of Orphan Products Development for drugs that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients annually. Register for free on Stock-Callers.com and get access to the latest PDF format report on CPRX at:
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock ended the day 1.48% higher at $11.69 and with a total trading volume of 286,794 shares. The Company's shares have gained 3.91% over the previous three months. The stock is trading 1.41% above its 200-day moving average. Additionally, shares of Momenta Pharmaceuticals, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, have an RSI of 46.63.
On August 4th, 2016, Momenta Pharmaceuticals reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa®, for Q2 2016. The company's net loss was $(21.0) million, or $(0.31) per share, for Q2 2016 compared to a net loss of $(2.2) million, or $(0.04) per share, for Q2 2015. As of June 30th, 2016, the company had cash, cash equivalents, and marketable securities of $336.9 million compared to $362.8 million at March 31st, 2016.
On September 07th, 2016, research firm Maxim Group downgraded the Company's stock rating from 'Hold' to 'Sell', issuing a target price of $6 per share. Download your free research report on MNTA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All